How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
50
CRSP Quote, Financials, Valuation and Earnings
Last price:
$50.87
Seasonality move
:
-4.79%
Day range:
$52.67 - $54.09
52-week range:
$30.04 - $78.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
121.69x
P/B ratio:
2.65x
Volume:
1.6M
Avg. volume:
1.7M
1-year change:
29.46%
Market cap:
$5.1B
Revenue:
$37.3M
EPS (TTM):
-$5.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
$3.9M | -$1.23 | -89.16% | -180.98% | $84.65 |
|
BEAM
Beam Therapeutics, Inc.
|
$13.2M | -$1.11 | 84.01% | -6.81% | $47.21 |
|
NTLA
Intellia Therapeutics, Inc.
|
$12.2M | -$0.96 | -5.45% | -10.49% | $23.86 |
|
NVS
Novartis AG
|
$14.1B | $2.00 | 3.71% | 14.01% | $140.00 |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.44 | 25.24% | 4402.9% | $404.19 |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$3.2B | $5.12 | 14.78% | 93.57% | $506.64 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
$53.35 | $84.65 | $5.1B | -- | $0.00 | 0% | 121.69x |
|
BEAM
Beam Therapeutics, Inc.
|
$29.29 | $47.21 | $3B | -- | $0.00 | 0% | 49.35x |
|
NTLA
Intellia Therapeutics, Inc.
|
$13.90 | $23.86 | $1.6B | -- | $0.00 | 0% | 25.33x |
|
NVS
Novartis AG
|
$148.91 | $140.00 | $285.7B | 20.31x | $3.99 | 2.68% | 5.39x |
|
ONC
BeOne Medicines Ltd.
|
$350.00 | $404.19 | $38.7B | 673.47x | $0.00 | 0% | 7.82x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$475.68 | $506.64 | $120.7B | 33.53x | $0.00 | 0% | 10.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 2.726 | 3.47% | 16.13x |
|
BEAM
Beam Therapeutics, Inc.
|
13.55% | 1.858 | 6.16% | 5.89x |
|
NTLA
Intellia Therapeutics, Inc.
|
11.58% | 2.838 | 4.9% | 5.57x |
|
NVS
Novartis AG
|
41.94% | -0.299 | 12.99% | 0.58x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | -0.083 | 5.05% | 2.09x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
9.58% | -0.699 | 1.84% | 1.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
BEAM
Beam Therapeutics, Inc.
|
$4.1M | -$126.8M | -38.05% | -44.48% | -1307.6% | -$86.5M |
|
NTLA
Intellia Therapeutics, Inc.
|
$8.8M | -$111.5M | -47.33% | -54.66% | -808.86% | -$76.9M |
|
NVS
Novartis AG
|
$10.3B | $4.2B | 19.37% | 33.87% | 30.24% | $5.7B |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$2.7B | $1.3B | 20.08% | 22.13% | 41.02% | $1.1B |
CRISPR Therapeutics AG vs. Competitors
-
Which has Higher Returns CRSP or BEAM?
Beam Therapeutics, Inc. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of -1162.38%. CRISPR Therapeutics AG's return on equity of -26.17% beat Beam Therapeutics, Inc.'s return on equity of -44.48%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B -
What do Analysts Say About CRSP or BEAM?
CRISPR Therapeutics AG has a consensus price target of $84.65, signalling upside risk potential of 58.67%. On the other hand Beam Therapeutics, Inc. has an analysts' consensus of $47.21 which suggests that it could grow by 61.2%. Given that Beam Therapeutics, Inc. has higher upside potential than CRISPR Therapeutics AG, analysts believe Beam Therapeutics, Inc. is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 9 1 BEAMBeam Therapeutics, Inc.13 2 0 -
Is CRSP or BEAM More Risky?
CRISPR Therapeutics AG has a beta of 1.700, which suggesting that the stock is 69.984% more volatile than S&P 500. In comparison Beam Therapeutics, Inc. has a beta of 2.070, suggesting its more volatile than the S&P 500 by 107.038%.
-
Which is a Better Dividend Stock CRSP or BEAM?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beam Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Beam Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or BEAM?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Beam Therapeutics, Inc. quarterly revenues of $9.7M. CRISPR Therapeutics AG's net income of -$106.4M is higher than Beam Therapeutics, Inc.'s net income of -$112.7M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Beam Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 121.69x versus 49.35x for Beam Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG121.69x -- $889K -$106.4M BEAMBeam Therapeutics, Inc.49.35x -- $9.7M -$112.7M
-
Which has Higher Returns CRSP or NTLA?
Intellia Therapeutics, Inc. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of -735.19%. CRISPR Therapeutics AG's return on equity of -26.17% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B NTLAIntellia Therapeutics, Inc.64.19% -$0.92 $846.4M -
What do Analysts Say About CRSP or NTLA?
CRISPR Therapeutics AG has a consensus price target of $84.65, signalling upside risk potential of 58.67%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $23.86 which suggests that it could grow by 71.63%. Given that Intellia Therapeutics, Inc. has higher upside potential than CRISPR Therapeutics AG, analysts believe Intellia Therapeutics, Inc. is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 9 1 NTLAIntellia Therapeutics, Inc.9 11 1 -
Is CRSP or NTLA More Risky?
CRISPR Therapeutics AG has a beta of 1.700, which suggesting that the stock is 69.984% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.054, suggesting its more volatile than the S&P 500 by 105.378%.
-
Which is a Better Dividend Stock CRSP or NTLA?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or NTLA?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. CRISPR Therapeutics AG's net income of -$106.4M is lower than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 121.69x versus 25.33x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG121.69x -- $889K -$106.4M NTLAIntellia Therapeutics, Inc.25.33x -- $13.8M -$101.3M
-
Which has Higher Returns CRSP or NVS?
Novartis AG has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of 28.26%. CRISPR Therapeutics AG's return on equity of -26.17% beat Novartis AG's return on equity of 33.87%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B NVSNovartis AG74.59% $2.02 $76.8B -
What do Analysts Say About CRSP or NVS?
CRISPR Therapeutics AG has a consensus price target of $84.65, signalling upside risk potential of 58.67%. On the other hand Novartis AG has an analysts' consensus of $140.00 which suggests that it could fall by -5.98%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 9 1 NVSNovartis AG1 5 2 -
Is CRSP or NVS More Risky?
CRISPR Therapeutics AG has a beta of 1.700, which suggesting that the stock is 69.984% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.516, suggesting its less volatile than the S&P 500 by 48.422%.
-
Which is a Better Dividend Stock CRSP or NVS?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 2.68% to investors and pays a quarterly dividend of $3.99 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRSP or NVS?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Novartis AG quarterly revenues of $13.9B. CRISPR Therapeutics AG's net income of -$106.4M is lower than Novartis AG's net income of $3.9B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Novartis AG's PE ratio is 20.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 121.69x versus 5.39x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG121.69x -- $889K -$106.4M NVSNovartis AG5.39x 20.31x $13.9B $3.9B
-
Which has Higher Returns CRSP or ONC?
BeOne Medicines Ltd. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of 8.84%. CRISPR Therapeutics AG's return on equity of -26.17% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About CRSP or ONC?
CRISPR Therapeutics AG has a consensus price target of $84.65, signalling upside risk potential of 58.67%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $404.19 which suggests that it could grow by 15.48%. Given that CRISPR Therapeutics AG has higher upside potential than BeOne Medicines Ltd., analysts believe CRISPR Therapeutics AG is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 9 1 ONCBeOne Medicines Ltd.19 0 1 -
Is CRSP or ONC More Risky?
CRISPR Therapeutics AG has a beta of 1.700, which suggesting that the stock is 69.984% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.467, suggesting its less volatile than the S&P 500 by 53.26%.
-
Which is a Better Dividend Stock CRSP or ONC?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or ONC?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. CRISPR Therapeutics AG's net income of -$106.4M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 673.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 121.69x versus 7.82x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG121.69x -- $889K -$106.4M ONCBeOne Medicines Ltd.7.82x 673.47x $1.4B $125M
-
Which has Higher Returns CRSP or VRTX?
Vertex Pharmaceuticals, Inc. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of 34.76%. CRISPR Therapeutics AG's return on equity of -26.17% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B VRTXVertex Pharmaceuticals, Inc.86.69% $4.20 $19.2B -
What do Analysts Say About CRSP or VRTX?
CRISPR Therapeutics AG has a consensus price target of $84.65, signalling upside risk potential of 58.67%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $506.64 which suggests that it could grow by 6.51%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 9 1 VRTXVertex Pharmaceuticals, Inc.18 7 1 -
Is CRSP or VRTX More Risky?
CRISPR Therapeutics AG has a beta of 1.700, which suggesting that the stock is 69.984% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.005%.
-
Which is a Better Dividend Stock CRSP or VRTX?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or VRTX?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. CRISPR Therapeutics AG's net income of -$106.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 33.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 121.69x versus 10.50x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG121.69x -- $889K -$106.4M VRTXVertex Pharmaceuticals, Inc.10.50x 33.53x $3.1B $1.1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 66x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
67
PFSI alert for Jan 30
PennyMac Financial Services, Inc. [PFSI] is down 31.3% over the past day.
Buy
78
GDXU alert for Jan 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 34.24% over the past day.
Sell
46
CVCO alert for Jan 30
Cavco Industries, Inc. [CVCO] is down 16.6% over the past day.
